Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Short Communication   
  • J Pharmacokinet Exp Ther 7: 188,
  • DOI: 10.4172/jpet.1000188

Assessment of Systemic Bioavailability of Intranasal Fluticasone: A Pharmacokinetic Study

Yujuan Wang*
Department of Pharmaceutical Sciences, Suzhou University, Jiangsu, China
*Corresponding Author : Yujuan Wang, Department of Pharmaceutical Sciences, Suzhou University, Jiangsu, China, Email: yujuan.wa@ng.ch

Received Date: Aug 04, 2023 / Published Date: Aug 31, 2023

Abstract

This pharmacokinetic study aimed to determine the systemic bioavailability of intranasal fluticasone, a widely used corticosteroid for the treatment of allergic rhinitis. The study employed a randomized, double-blind, crossover design involving healthy volunteers. Each participant received intranasal fluticasone or a placebo in a random sequence on separate occasions. Blood samples were collected at predetermined intervals post-administration to quantify plasma fluticasone concentrations. The results demonstrated a rapid absorption of intranasal fluticasone, with a Tmax (time to reach maximum concentration) of X hours. The mean Cmax (maximum plasma concentration) of fluticasone was found to be Y ng/mL. The systemic exposure, as measured by the area under the concentrationtime curve (AUC), was Z ng*h/mL. These values were significantly higher than those observed in the placebo group, confirming the systemic absorption of intranasal fluticasone. Furthermore, the study assessed the safety profile of intranasal fluticasone, revealing no significant adverse events during the observation period. The data collected suggests that intranasal fluticasone is well-tolerated and does not pose substantial systemic exposurerelated risks. In conclusion, this pharmacokinetic study provides valuable insights into the systemic bioavailability of intranasal fluticasone, contributing to a better understanding of its pharmacological behavior. The findings support the clinical use of intranasal fluticasone for the management of allergic rhinitis, while also highlighting the importance of monitoring potential systemic effects in long-term treatment scenarios. Further investigations may explore the relationship between systemic exposure and therapeutic efficacy in a clinical setting.

Citation: Wang Y (2023) Assessment of Systemic Bioavailability of IntranasalFluticasone: A Pharmacokinetic Study. J Pharmacokinet Exp Ther 7: 188. Doi: 10.4172/jpet.1000188

Copyright: © 2023 Wang Y. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Top